retatrutide triple agonist obesity phase 2 trial Eli Lilly's 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide triple agonist gip glp-1

Inflammation First: How GLP-1s Act Independently of Weight Loss A groundbreaking finding in GLP-1 clinical trials is that these compounds can significantly reduce inflammatory markers and improve inflammatory conditions before any substantial changes in body weight or blood glucose levels are observed

Wegovy has a retail price of around $1,350 for a four-week supply.[3] Insurance coverage varies widely, and many insurance plans do not cover medications for obesity.[4] Supply shortages have also affected access to GLP-1 medications

*Product may contain benzyl alcohol as an inactive ingredient Contraindications for Benzyl Alcohol This preparation is not advised in patients who are sensitive to cobalt and/or vitamin B12

The key is to stick with your B12 injection schedule and let it do its thing